OR WAIT null SECS
Skin clearance and route of administration drove treatment choices among 202 patients with psoriasis in the ENCOMPASS-PP discrete choice experiment.
Individuals living with psoriasis who were eligible for systemic treatment weighed the likelihood of skin clearance more heavily than any other treatment feature, new data suggest, followed by whether a drug is taken orally or via injection.
These data come from early results of a multicountry discrete choice experiment presented during the 2026 Fall Clinical Dermatology Conference in Las Vegas, Nevada.¹ Fasting requirements and injection frequency had little influence on patients’ decisions.
The number of systemic options for moderate to severe psoriasis keeps growing, and comparative evidence across biologic and oral agents has expanded along with it.² Measuring which treatment attributes patients value most may help clinicians tailor shared decision-making as the choices multiply.
The ENCOMPASS Patient Preference (ENCOMPASS-PP) study was led by Jennifer Soung, MD, of Southern California Dermatology. Her co-investigators included Linda Stein Gold, MD, of Henry Ford Health, and Mona Shahriari, MD, of Central Connecticut Dermatology.¹ The research was conducted in collaboration with Johnson & Johnson Innovative Medicine, Thermo Fisher Scientific, and the National Psoriasis Foundation.
The study investigators built the survey following ISPOR good research practices. The team drew on a targeted literature review, input from a multidisciplinary steering committee, and patient interviews, which were implemented both to identify concepts and to pretest the survey.¹ Participants repeatedly chose between hypothetical treatment profiles defined by 7 attributes:
The initial phase enrolled 202 participants who met International Psoriasis Council criteria for systemic treatment, from the UK (n = 81), US (n = 68), and Australia (n = 53).¹ The mean age was 44.8 years; 41.1% were female, 43.5% had used a biologic, and 86.1% had used an oral therapy. Preferences were estimated with a multinomial logit model and expressed as relative attribute importance (RAI).
Skin clearance dominated decision-making, with an RAI of 20.9% for clearance at 52 weeks and 18.7% for clearance at 16 weeks.¹ Patients valued short-term and long-term clearance at roughly similar levels.
A second tier of attributes carried comparable weight:
Fasting requirements for oral therapy had the least influence (RAI, 4.0%). Spacing out injections didn’t meaningfully change patients’ choices. Preferences didn’t differ significantly between dosing every 16 weeks and dosing every 12, 8, or 4 weeks.¹
In an exploratory question, participants reconsidered a treatment profile they had initially chosen after it was given a 10% annual risk of acne.¹ More than one-third (35%) said they would switch to the alternative with no acne risk.
The authors concluded that route of administration, along with efficacy and the risks of infection and gastrointestinal symptoms, shapes how patients choose among systemic psoriasis therapies.¹ The results reflect an early subset from 3 countries, and most participants had limited body surface area involvement. Because hypothetical scenarios may not mirror real-world choices, data from the full multicountry cohort will help clarify these preferences.
Editor’s note: This summary has been edited for grammar and clarity using artificial intelligence tools.
References
